NDLI: Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection

Content Provider	Springer Nature Link
Author	Sadekar, S. Figueroa, I. Tabrizi, M.
Copyright Year	2015
Abstract	Antibody drug conjugates (ADCs) are a multi-component modality comprising of an antibody targeting a cell-specific antigen, a potent drug/payload, and a linker that can be processed within cellular compartments to release payload upon internalization. Numerous ADCs are being evaluated in both research and clinical settings within the academic and pharmaceutical industry due to their ability to selectively deliver potent payloads. Hence, there is a clear need to incorporate quantitative approaches during early stages of drug development for effective modality design and target selection. In this review, we describe a quantitative approach and framework for evaluation of the interplay between drug- and systems-dependent properties (i.e., target expression, density, localization, turnover, and affinity) in order to deliver a sufficient amount of a potent payload into the relevant target cells. As discussed, theoretical approaches with particular considerations given to various key properties for the target and modality suggest that delivery of the payload into particular effect cells to be more sensitive to antigen concentrations for targets with slow turnover rates as compared to those with faster internalization rates. Further assessments also suggest that increasing doses beyond the threshold of the target capacity (a function of target internalization and expression) may not impact the maximum amount of payload delivered to the intended effect cells. This article will explore the important application of quantitative sciences in selection of the target and design of ADC modalities.
Starting Page	828
Ending Page	836
Page Count	9
File Format	PDF
ISSN	12341234
Journal	The AAPS Journal
Volume Number	17
Issue Number	4
e-ISSN	15507416
Language	English
Publisher	Springer US
Publisher Date	2015-05-02
Publisher Institution	American Association of Pharmaceutical Scientists
Publisher Place	New York
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Pharmacology/Toxicology Biochemistry Biotechnology Pharmacy
Content Type	Text
Resource Type	Article

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection

Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry

Antibody Drug Conjugates: Preclinical Considerations

Immunogenicity of Antibody Drug Conjugates: Bioanalytical Methods and Monitoring Strategy for a Novel Therapeutic Modality

Antibody Drug Conjugates: Nonclinical Safety Considerations

Evolving Strategies for Target Selection for Antibody-Drug Conjugates

ADME of Antibody–Maytansinoid Conjugates

Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates

Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection

Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection

Similar Documents

Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection

Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry

Antibody Drug Conjugates: Preclinical Considerations

Immunogenicity of Antibody Drug Conjugates: Bioanalytical Methods and Monitoring Strategy for a Novel Therapeutic Modality

Antibody Drug Conjugates: Nonclinical Safety Considerations

Evolving Strategies for Target Selection for Antibody-Drug Conjugates

ADME of Antibody–Maytansinoid Conjugates

Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates

Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection

Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection